Discovery of a Novel M1 Selective Antagonist, PIPE-307, for the Treatment of Multiple Sclerosis

/in , /by

Kym I Lorrain, Michael M Poon, Alexander Broadhead, Karin J Stebbins, Austin Chen, Jill Baccei, Ari J Green, Jonah R Chan, Daniel S Lorrain

Presented at Neuroscience 2021

Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE

/in , /by

Thomas O. Schrader, Yifeng Xiong, Ariana O. Lorenzana, Alexander Broadhead, Karin J. Stebbins, Michael M. Poon, Christopher Baccei, and Daniel S. Lorrain

ACS Medicinal Chemistry Letters

PIPE-359, a novel, potent and selective M1 muscarinic receptor antagonist as a therapeutic approach for remyelination in multiple sclerosis

/in , /by

Karin J Stebbins, Michael M Poon, Alexander Broadhead, Geraldine Edu, Ariana Lorenzana, Kym I Lorrain, Thomas Schrader, Yifeng Xiong, Jill Baccei, Christopher Baccei, Ari J Green

Presented at Neuroscience 2019

Small molecule inhibition of the muscarinic M1 acetylcholine receptor by potent, selective antagonists facilitate OPC differentiation

/in , /by

Michael M Poon, Kym I Lorrain, Ariana O Lorenzana, Karin J Stebbins, Alexander Broadhead, Thomas O Schrader, Yifeng Xiong, Jill Baccei, Ari J

Presented at Neuroscience 2019

The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE)

/in , /by

Geraldine C Edu, Karin J Stebbins, Alexander R Broadhead, Michael M Poon, Ariana O Lorenzana, Thomas Schrader, Yifeng Xiong, Jill Baccei, Ari J Green, Jonah R Chan, and Daniel S Lorrain

Presented at Neuroscience 2019

©2025 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin